From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, debates the benefits of abiraterone compared to standard chemotherapy for treating patients with prostate cancer. Prof. Montorsi also highlights unnecessary biopsies, and how these could potentially be avoided using fusion techniques. Prof. Montorsi mentions that patients should be involved in their own management plans, and that their preference of therapy should be taken into consideration. He urges healthcare professionals to regularly keep up to date on novel therapies and changes in practice to provide the optimal care for patients.
Debating the future of prostate cancer management
